Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; Potential marker of disease recurrence

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Rengucci, Claudia ^a   De Maio, Giulia ^a   Gardini, Andrea Casadei ^a   Zucca, Mattia ^a   Scarpi, Emanuela ^a   Zingaretti, Chiara ^b   Foschi, Giovanni ^a   Tumedei, Maria Maddalena ^a   Molinari, Chiara ^a   Saragoni, Luca ^c   Puccetti, Maurizio ^d   Amadori, Dino ^a   Zoli, Wainer ^a   Calistri, Daniele ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b National Institute of Molecular Genetics   (Italy)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

^d SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

Colorectal adenoma; Gene promoter methylation profile; Pre neoplastic lesion classification; Prognostic marker; Risk of recurrence

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; FRAGILE HISTIDINE TRIAD PROTEIN; GLUTATHIONE TRANSFERASE P1; PROTEIN MLH1; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRECANCER; PROMOTER REGION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE; CARCINOGENESIS; COLORECTAL TUMOR; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOGENESIS; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENOMICS; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES;

EID: 84906545368     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0065-x     Document Type: Article

References (39)

1. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. JR Jass, Histopathology 2007 50 113 130 10.1111/j.1365-2559.2006.02549.x 17204026
2. Hereditary colorectal cancer. HT Lynch, A de la Chapelle, N Engl J Med 2003 348 919 932 10.1056/NEJMra012242 12621137
3. The genetics of hereditary colon cancer. AK Rustgi, Genes Dev 2007 21 2525 2538 10.1101/gad.1593107 17938238
4. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. AG Zauber, SJ Winawer, MJ O'Brien, I Lansdorp-Vogelaar, M Van Ballegooijen, BF Hankey, W Shi, JH Bond, M Schapiro, JF Panish, ET Stewart, JD Waye, N Engl J Med 2012 366 687 696 10.1056/NEJMoa1100370 22356322
5. Colonoscopic polypectomies and recommendations on the colonoscopy follow-up intervals depending on endoscopic and histopathological findings. M Simunic, N Perkovic, B Rosic-Despalatovic, A Tonkic, Z Ardalic, M Titlic, M Maras-Simunic, Acta Inform Med 2013 21 166 169 10.5455/aim.2013.21.166-169 24167384
6. Molecular genetics of colorectal cancer. ER Fearon, Annu Rev Pathol 2011 6 479 507 10.1146/annurev-pathol-011110-130235 21090969
7. The American College of Gastroenterology Emily Couric Lecture-the adenoma-carcinoma sequence revisited: has the era of genetic tailoring finally arrived? DJ Ahnen, Am J Gastroenterol 2011 106 190 198 10.1038/ajg.2010.423 21266962
8. The epigenomics of cancer. PA Jones, SB Baylin, Cell 2007 128 683 692 10.1016/j.cell.2007.01.029 17320506
9. The history of cancer epigenetics. AP Feinberg, B Tycko, Nat Rev Cancer 2004 4 143 153 10.1038/nrc1279 14732866
10. DNA methylation in colorectal cancer-impact on screening and therapy monitoring modalities? M Zitt, M Zitt, HM Müller, Dis Markers 2007 23 51 71 10.1155/2007/891967 17325426
11. Epigenetic changes in colorectal cancer. Y Kondo, JP Issa, Cancer Metastasis Rev 2004 23 29 39 10.1023/A:1025806911782 15000147
12. Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence. MF De Maat, CJ van de Velde, MP van der Werff, H Putter, N Umetani, EM Klein-Kranenbarg, RR Turner, JHJM Van Krieken, A Bilchik, RAEM Tollenaar, DSB Hoon, J Clin Oncol 2008 26 2327 2335 10.1200/JCO.2007.14.0723 18467724
13. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. O Hartmann, F Spyratos, N Harbeck, D Dietrich, A Fassbender, M Schmitt, S Eppenberger-Castori, V Vuaroqueaux, F Lerebours, K Welzel, S Maier, A Plum, S Niemann, JA Foekens, R Lesche, JW Martens, Clin Cancer Res 2009 15 315 323 10.1158/1078-0432.CCR-08-0166 19118060
14. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. L Richiardi, V Fiano, L Vizzini, L De Marco, L Delsedime, O Akre, AG Tos, F Merletti, J Clin Oncol 2009 27 3161 3168 10.1200/JCO.2008.18.2485 19470943
15. Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. M Di Domenico, A Santoro, C Ricciardi, M Iaccarino, S Iaccarino, M Freda, A Feola, F Sanguedolce, S Losito, D Pasquali, A Di Spiezio Sardo, G Bifulco, C Nappi, P Bufo, M Guida, G De Rosa, A Abbruzzese, M Caraglia, G Pannone, Cancer Biol Ther 2011 12 447 457 10.4161/cbt.12.5.15963 21709441
16. CpG island methylator phenotype in cancer. JP Issa, Nat Rev Cancer 2004 4 988 993 10.1038/nrc1507 15573120
17. CpG island methylation in gastroenterologic neoplasia: a maturing field. A Rashid, JPJ Issa, Gastroenterology 2004 127 1578 1588 10.1053/j.gastro.2004.09.007 15521024
18. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. DJ Weisenberger, KD Siegmund, M Campan, J Young, TI Long, MA Faasse, GH Kang, M Widschwendter, D Weener, D Buchanan, H Koh, L Simms, M Barker, B Leggett, J Levine, M Kim, AJ French, SN Thibodeau, J Jass, R Haile, PW Laird, Nat Genet 2006 38 787 793 10.1038/ng1834 16804544
19. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. T Hinoue, DJ Weisenberger, F Pan, M Campan, M Kim, J Young, M Kim, J Young, VL Whitehall, BA Leggett, PW Laird, PLoS One 2009 4 8357 10.1371/journal.pone.0008357
20. DNA demethylation and pericentromeric rearrangements of chromosome 1. W Ji, R Hernandez, XY Zhang, GZ Qu, A Frady, M Varela, M Ehrlich, Mutat Res 1997 379 33 41 10.1016/S0027-5107(97)00088-2 9330620
21. The CpG Island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. A Goel, T Nagasaka, CN Arnold, T Inoue, C Hamilton, D Niedzwiecki, C Compton, RJ Mayer, R Goldberg, MM Bertagnolli, CR Boland, Gastroenterology 2007 132 127 138 10.1053/j.gastro.2006.09.018 17087942
22. Methylation profiling of rectal cancer identifies novel markers of early-stage disease. KJ Leong, W Wei, LA Tannahill, GM Caldwell, CE Jones, DG Morton, GM Matthews, SP Bach, Br J Surg 2011 98 724 734 10.1002/bjs.7422 21360524
23. Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer. JW Moon, SK Lee, JO Lee, N Kim, YW Lee, SJ Kim, HJ Kang, J Kim, HS Kim, SH Park, J Exp Clin Cancer Res 2014 33 4 24393480
24. Epigenetics and colorectal cancer pathogenesis. K Bardhan, K Liu, Cancers (Basel) 2013 5 676 713 10.3390/cancers5020676
25. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. MF Kane, M Loda, GM Gaida, J Lipman, R Mishra, H Goldman, JM Jessup, R Kolodner, Cancer Res 1997 57 808 811 9041175
26. Balancing repair and tolerance of DNA damage caused by alkylating agents. D Fu, JA Calvo, LD Samson, Nat Rev Cancer 2012 12 104 120 22237395
27. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. MF Lavin, Nat Rev Mol Cell Biol 2008 9 759 769 10.1038/nrm2514 18813293
28. ATM and related protein kinases: safeguarding genome integrity. Y Shiloh, Nat Rev Cancer 2003 3 155 168 10.1038/nrc1011 12612651
29. Hits, Fhits and Nits: beyond enzymatic function. K Huebner, JC Saldivar, J Sun, H Shibata, T Druck, Adv Enzyme Regul 2011 51 208 217 10.1016/j.advenzreg.2010.09.003 21035495
30. FHIT: doubts are clear now. A Wali, Scientific World Journal 2010 10 1142 1151 10.1100/tsw.2010.110 20563537
31. Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer. RA Al-Temaimi, S Jacob, W Al-Ali, DA Thomas, F Al-Mulla, J Histochem Cytochem 2013 61 627 638 10.1369/0022155413497367 23797051
32. Epigenetic modifications and human disease. A Portela, M Esteller, Nat Biotechnol 2010 28 1057 1068 10.1038/nbt.1685 20944598
33. TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status. M Herreros-Villanueva, P Muñiz, C García-Girón, M Cavia-Saiz, MJ Del Corral, J Transl Med 2010 8 15 10.1186/1479-5876-8-15 20146801
34. p63/p73 in the control of cell cycle and cell death. N Allocati, C Di Ilio, V De Laurenzi, Exp Cell Res 2012 318 1285 1290 10.1016/j.yexcr.2012.01.023 22326462
35. BRCA gene structure and function in tumor suppression: a repair-centric perspective. CG Murphy, ME Moynahan, Cancer J 2010 16 39 47 10.1097/PPO.0b013e3181cf0204 20164689
36. CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer. MY Huang, JY Wang, HJ Chang, CW Kuo, TS Tok, SR Lin, Oncol Rep 2011 25 1297 1306 10.3892/or.2011.1171 21344162
37. Epigenetics and colorectal cancer. VV Lao, WM Grady, Nat Rev Gastroenterol Hepatol 2011 8 686 700 10.1038/nrgastro.2011.173 22009203
38. Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers. H Noda, Y Kato, H Yoshikawa, M Arai, K Togashi, H Nagai, F Konishi, Y Miki, J Exp Clin Cancer Res 2006 25 2 235 242 16918136
39. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. V Casadio, C Molinari, D Calistri, M Tebaldi, R Gunelli, L Serra, F Falcini, C Zingaretti, R Silvestrini, D Amadori, W Zoli, J Exp Clin Cancer Res 2013 32 94 24252461